Background. We describe the emergence and spread of Klebsiella pneumoniae carbapenemase 2 (KPC-2)-producing K. pneumoniae at a Greek University hospital.
that species was mainly the result of dissemination of the bla VIM-1 gene [2] [3] [4] [5] [6] .
In late 2007, 2 publications reported the emergence of bla KPC-2 in K. pneumoniae isolates in Europe. Both of the involved patients were first hospitalized in Crete, Greece [7, 8] . During 2007 During -2008 , outbreaks of infection due to K. pneumoniae carbapenemase 2 (KPC-2)-producing K. pneumoniae were identified at 2 hospitals (1 in Crete [9] and 1 in Thessaloniki [10] ). A surveillance study organized from February through December 2008 at 21 hospitals in Greece identified the presence of KPC-2-producing K. pneumoniae at 18 hospitals in Athens, Crete, and Thessaloniki. Among the 171 isolates studied, 97.1% belonged to the same pulse type, which was found at 17 hospitals [11] , suggesting a nationwide dissemination of a hyperepidemic clone.
These findings were in accordance with an important observation that a dominant KPC-2-producing K. pneumoniae strain belonging to the ST 258 lineage has disseminated throughout the United States [12] and was later identified in Israel and Greece [13] . There is evidence that the Greek major clone may have originated in Israel [11] , suggesting the possibility of global dissemination of 1 strain type of KPC-2-producing K. pneumoniae. The aim of the present study was to describe the emergence of KPC-2-producing K. pneumoniae at University General Hospital ATTIKON, in Athens, Greece, focusing on the epidemiological, microbiological, and clinical characteristics of the outbreak and comparing our experience with that of the previously described epidemic of metallo-blactamase (MBL)-producing K. pneumoniae infection in the same setting [4] .
MATERIALS AND METHODS

Setting.
During the study period (January 2007-December 2008), there were 635 beds in use in our hospital with ∼30,000 admissions annually. From January 2007 through October 2008, the hospital's general (surgical and medical) intensive care unit (ICU) had 18 beds in use. Three more beds were added in October 2008. The ICU is separated into 3 compartments, each including an isolation room. Nursing and medical staff are dedicated in each compartment. Antibiotic policies and infection control measures are described elsewhere [4] .
Study design. This was a retrospective observational cohort study. The computerized databases of the microbiology laboratories were retrospectively searched. All K. pneumoniae isolates obtained during the study period from any clinical specimen that exhibited an imipenem or meropenem minimum inhibitory concentration (MIC) 11 mg/mL and a negative imipenem-EDTA disk synergy test result were further studied for the presence of KPC. Medical records of all patients colonized or infected with KPC-producing K. pneumoniae were retrospectively reviewed by an independent physician. Follow-up was possible until discharge from the hospital or death. The duration of colonization with a KPC-producing isolate before infection was also available, because ICU patients were routinely screened biweekly with use of surveillance cultures [14] .
Written consent to use data from patients' files was given by each patient or by a first-degree relative at the time of hospital admission. With regard to the route of acquisition of KPC-2-producing K. pneumoniae, horizontal transmission during the current hospitalization was hypothesized for patients who had a negative result of first screening, whereas isolates that were identified on the day of admission or during the first 72 h were characterized as imported from another hospital. The route of acquisition remained undetermined for patients who were screened for the first time 172 h after admission and were positive for KPC-2-producing K. pneumoniae. For the clinical and microbiological diagnosis of infections, previously published criteria were used [15] [16] [17] [18] [19] .
Treatment outcome was evaluated on day 7. Cure was defined as no clinical or laboratory evidence of infection. Improvement was defined as partial resolution of signs, symptoms, and laboratory parameters of infection. Cure and improvement were characterized as a successful outcome; all other outcomes were characterized as failures.
Microbiological studies. One isolate per patient (either the first colonizing or the first pathogenic isolate identified) was submitted for further study. Species identification of isolated bacteria and MIC determinations were performed using an automated system (BD Phoenix automated microbiology system; BD Diagnostic Systems). MICs of imipenem, meropenem, ertapenem, gentamicin, and fosfomycin were also evaluated with agar dilution, in accordance with the Clinical Laboratory Standards Institute (CLSI) [20] , whereas MICs of colistin and tigecycline were determined using Etest (AB Biodisk), in accordance with the manufacturer's instructions. Results were interpreted in accordance with CLSI criteria [20] , with the exception of those for fosfomycin, colistin, and tigecycline. For these agents, the break points proposed by European Committee on Antimicrobial Susceptibility Testing [21] were used (susceptibility, р32 for fosfomycin, р2 mg/mL for colistin, and р1 mg/mL for tigecycline), because relevant break points were not available from CLSI. All isolates were screened for MBL production with use of the EDTA-imipenem disk synergy test [22] , and isolates for which results were negative were submitted to imipenem-boronic acid disk synergy test as a screening for KPC production [23] . Isoelectric focusing of sonic extracts was performed on precast polyacrylamide gels with a pH 3-10 gradient (Phast Gel IEF 3-9; Amersham Biosciences) for b-lactamase detection. The presence of bla KPC was confirmed by polymerase chain reaction (PCR) with specific primers [24] . PCR for bla TEM , bla SHV , and bla CTX-M was performed as described elsewhere [25, 26] . Sequencing of PCR products was performed by MWG (Eurofins MWG Operon). For sequence analysis, the BLAST program from the National Center for Biotechnology Information Web site was used (http://www.ncbi.nlm.nih.gov/ BLAST).
The genetic relatedness of all KPC-2-producing K. pneumoniae isolates was evaluated using pulsed-field gel electrophoresis (PFGE) analysis. Pulse types were compared with those of MBLproducing K. pneumoniae isolated in our institution. DNA was prepared in accordance with standard PFGE methods, and chromosomal restriction fragments obtained after SpeI cleavage were visually compared [27] .
Environmental cultures. During November 2008, a point prevalence survey of environmental colonization of KPC-producing K. pneumoniae was conducted in our ICU. Samples were obtained for culture by rubbing premoistened swabs repeatedly over designated sites in the immediate vicinity of the patient, over equipment used in patient care, and in the general areas in all the compartments of the ICU. Swab samples were inoculated on MacConkey agar (Becton Dickinson) plates containing imipenem. Procedures of identification and phenotypic and susceptibility testing of isolated gram-negative bacteria were the same as described above.
Statistical analysis. Comparative analyses were performed using the x 2 test or the Fischer's exact test for assessment of differences in proportions and Student's t test for the continuous variables, as appropriate. All tests were 2-tailed, and was considered to indicate statistical significance. P ! .05
RESULTS
In March 2008, 2 K. pneumoniae isolates exhibiting nonsusceptibility to carbapenems but a phenotypic test negative for MBL production were identified. This prompted a database search for similar cases (see above for case definition) that extended retrospectively through January 2007 and prospectively through December 2008. During the study period, a total of 50 patients were either infected (18 [36%] ) or colonized (32 [64%] ) with a K. pneumoniae strain producing a non-MBL carbapenemase, which was identified by PCR and sequencing to be KPC-2. Susceptibilities of the 50 K. pneumoniae isolates to various antimicrobials are shown in Table 1 . All isolates shared a common multidrug resistance phenotype, although initial MIC testing by the automated Phoenix system showed that 4% and 10% were susceptible to imipenem and meropenem, respectively. PFGE analysis of the 50 K. pneumoniae isolates identified 4 different clonal types, designated A-D (data not shown). The predominant clonal type was A, which comprised 41 single patient isolates (82%) and included subtypes A1 ( ), A2 n p 19 ( ), A3 ( ), A4 ( ), and A5 ( ), differing n p 19 n p 1 n p 1 n p 1 by 2-4 bands from A1. Six isolates (12%) were clonal type B, including subtypes B1 ( ) and B2 ( ), differing by 4-n p 5 n p 1 6 bands from each other, whereas 1 (2%) and 2 (4%) isolates were clonal types C and D, respectively. The temporal distribution of KPC producers and their respective clonal type are shown in Figure 1 . Pulse types were unrelated to those of MBL- producing K. pneumoniae isolated during the same period at our institution (data not shown).
In all isolates, molecular studies revealed, in addition to KPC-2 (pI 6.8), a TEM-1-like enzyme and a b-lactamase (pI 7.6), which was identified as the intrinsic SHV-11 in representative isolates. However, the single isolate belonging to clonal type C harbored the chromosomally encoded bla LEN-19 gene. SHV-12 (pI 8.2) was identified in all clonal type A isolates and in 2 clonal type D isolates, and the isolates of B2 and C clonal types also produced CTX-M-15 (pI 8.9).
Sporadic cases of KPC-2-producing K. pneumoniae infection were identified from September 2007 through May 2008, representing a multiclonal cluster. Clonal type B was imported by a patient who was hospitalized at 3 other tertiary care hospitals in the Athens area before admission to the ATTIKON ICU, and it was responsible for a limited outbreak because of dissemination to at least 3 more patients in the same ICU compartment. The first isolate belonging to the epidemic clone (A) was introduced in the general ICU in February 2008 by a patient who was transferred from another hospital and was already colonized at admission. This strain was horizontally transmitted to at least 1 additional patient in the same compartment of the ICU and then disappeared. A strain belonging to the same clonal group was reintroduced in the ICU in August 2008 by another patient already colonized after prolonged hospitalization at another hospital. Thirty-eight patients (76%) with KPC-2-producing K. pneumoniae colonization or infection were identified from August through December 2008. Only isolates belonging to clonal group A were responsible for clinical infections in our cohort.
On the basis of criteria described in Materials and Methods, among ICU patients, KPC-2-producing K. pneumoniae was acquired by cross-transmission in the ICU in 20 patients (58.8%), it was imported in 10 (29.4%), and the route of acquisition remained undetermined for 4 (11.8%). Among non-ICU patients, KPC-2-producing K. pneumoniae was acquired by cross-transmission during the current hospitalization in 4 patients (25%), it was imported in 2 (12.5%), and the route of acquisition remained undefined in 10 (62.5%), because active surveillance was not routinely performed outside the ICU. Among 114 environmental samples from the ICU area that were cultured, results were positive for only 1, which was recovered from the connector of the endotracheal tube of a patient with known colonization by KPC-2-producing K. pneumoniae.
Various clinical characteristics of patients from whom KPC-2-producing K. pneumoniae was isolated are presented in Table  2 . Most of the patients (34 [68%] ) were hospitalized in the Table 3 . Fifty percent of these patients were in the ICU (8 patients in the general ICU and 1 in the cardiac ICU) at the time of diagnosis of KPC-producing K. pneumoniae infection. The mean age was 67 years (range, 42-82 years), and 10 patients (55.6%) were male. The median Acute Physiology and Chronic Health Evaluation II (APACHE II) score was 17 (range, 8-37). The mean length of stay in our hospital before infection was 23 days (range, 1-100 days); however, 10 patients were transferred from another hospital, and the total mean length of hospital stay before infection was 27 days (range, 1-100 days; data not shown). All of the patients in this cohort had at least 1 recent hospitalization during the previous 3 months. Among 9 patients for whom surveillance cultures were performed at admission and weekly thereafter, colonization with KPC-producing K. pneumoniae preceded clinical infection in 5 (55.6%) for a mean duration of 10 days (range, 2-18 days). Previous rectal colonization was identified in only 2 (22.2%) of the patients with clinical infection.
Bacteremia was diagnosed in 14 patients (77.8%; 8 primary, 2 secondary, and 4 catheter-related cases), surgical site infection was diagnosed in 2 (11.1%), lower respiratory tract infection was diagnosed in 2 (1 with secondary bacteremia), and urinary tract infection was diagnosed in 1. Three (17.6%) of the infected patients were receiving a carbapenem-containing antimicrobial regimen when the infection was diagnosed, and 4 (23.5%) were receiving piperacillin-tazobactam (Table 3) . Infection was successfully treated in 12 patients (66.7%) with an antimicrobial regimen containing colistin either as the only active antimicrobial (6 patients) or with an active aminoglycoside (1), tigecycline (3), or a carbapenem and catheter removal (1). Treatment was considered to be unsuccessful in 6 patients (33.3%). Patient 4 received colistin as the active antimicrobial on day 8 and had 2 recurrences of bacteremia after 10 and 28 days of the first diagnosis. Patients 10, 12, 13, and 14 were unsuccessfully treated with a colistin combination regimen; the latter 3 patients were profoundly immunosuppressed. Patient 18 developed a surgical site infection and recurrent bacteremia 11 days after the first infection and a second recurrence 3 days later with a phenotypically and genotypically identical isolate.
Among the 18 patients, infection due to KPC-producing K. pneumoniae was considered to have contributed to death in 5 (27.8%), whereas the crude mortality among the cohort of infected patients was 61.1%. The total mean length of hospital stay for infected patients was 62 days (range, 8-161 days).
DISCUSSION
We described an outbreak of KPC-2-producing K. pneumoniae infection at an institution where VIM-1-producing K. pneumoniae had reached levels of endemicity. In the hospital's ICU in particular, the prevalence rate of K. pneumoniae with an MBL phenotype was 26.5 single patient isolates per 100 admissions in 2006 and 32.9 single patient isolates per 100 admissions in 2007 and decreased to 13.5 single patient isolates per 100 admissions in 2008 (our unpublished data). Of interest, the lowest rate of MBL-producing K. pneumoniae coincided with the highest rate of KPC-2-producing K. pneumoniae (9.9 single patient isolates per 100 admissions), suggesting a possible replacement of VIM-1 K. pneumoniae by the KPC-2-producing K. pneumoniae.
In a comparison with our previous experience with MBLproducing Enterobacteriaceae causing clinical infections in the same setting during a 3-year period (2003) (2004) (2005) (2006) [4] , we noticed that patients with KPC-2-producing K. pneumoniae infection were younger (mean age, 66.5 vs 68.7 years; ) P p .65 and less seriously ill (median APACHE II score, 17 vs 22;
). The infection occurred after prolonged hospitaliza-P p .14 tion (mean duration, 23 days) in both cohorts; however, previous colonization was identified in 82% of patients with infection due to MBL-producing Enterobacteriaceae, compared with 55.6% of patients with KPC-2-producing K. pneumoniae infection (
). The mean duration of colonization before P p .59 infection was shorter for patients with KPC-2-producing K. pneumoniae (9.8 
days vs 19 days;
). Prior rectal colo-P p .35 nization was identified in 72.7% of patients with infection due to MBL-producing Enterobacteriaceae, compared with 22.2% of patients with KPC-2-producing K. pneumoniae infection ( ). Bacteremia was the most common site of infection P p .25 in both cohorts. Forty-seven percent of patients with infection due to KPC-2-producing K. pneumoniae had received carbapenem therapy 3 months before infection, compared with 62.5% of patients with infection due to MBL-producing Enterobacteriaceae ( ). Crude mortality among patients in-P p .63 fected with MBL-producing Enterobacteriaceae was 68.8%, compared with 61.1% among patients infected with KPC-2-producing K. pneumoniae ( ); however, attributable mor-P p .83 tality was 18.8% and 27.8%, respectively ( ). Although P p .71 the methods of MIC determination differed between these studies, a higher percentage of MBL-producing Enterobacteriaceae isolates exhibited susceptibility to imipenem (47%) or meropenem (58.8%). Finally, molecular epidemiology studies con- Minimum inhibitory concentration break points applied for susceptibility were imipenem and MER, р4 mg/mL; ertapenem, р2 mg/mL; GEN and tobramycin, р4 mg/mL; AMK, р16 mg/mL; netilmicin, р8 mg/mL; minocycline, р4 mg/mL; CIP, р1 mg/mL; trimethoprim-sulfamethoxazole, р2 mg/mL/38 mg/mL; FOS, р32 mg/mL; COL, р2 mg/mL; and TIG, р1 mg/mL [20, 21] .
Downloaded from https://academic.oup.com/cid/article-abstract/50/3/364/394395 by guest on 27 February 2019 firmed that the outbreak of MBL-producing K. pneumoniae infection was polyclonal, whereas that of KPC-2-producing K. pneumoniae infection was monoclonal. These differences suggest that the hyperendemic strain of KPC-2-producing K. pneumoniae, in addition to dissemination advantage, may even be more virulent than the MBL-producing strains of K. pneumoniae circulating in our hospital, although a matched case-control study is required for direct comparison of outcome between infections by K. pneumoniae strains with different resistance determinants.
Studies from Israel and the United States have identified poor functional status, ICU stay, transplantation, mechanical ventilation, prolonged hospitalization, and receipt of antibiotics [29, 30] as risk factors for acquisition of KPC-2-producing K. pneumoniae. The observational design of our study did not allow for any conclusions regarding potential risk factors for KPC-2-producing K. pneumoniae acquisition at our institution.
The epidemiological profile of the present outbreak differs from that of the multiclonal outbreak of KPC-2-producing K. pneumoniae that was observed in Israel [31] ; however, it is reminiscent of the primarily clonal outbreak described in US hospitals [25, 32, 33] . In the present study, the monoclonal type of the outbreak and the failure to identify a common source or an environmental reservoir implicate patient-to-patient transmission as the main mechanism of spread of KPC-2-producing K. pneumoniae. On the basis of the published literature, it appears that this outbreak was part of a nationwide outbreak caused by 1 predominant KPC-2-producing K. pneumoniae strain [11] , but the strains isolated in our institution were found to also accumulate other b-lactam resistance enzymes (TEM-1-like, SHV-11, SHV-12, LEN-19, and CTX-M-15). In particular, the coexistence of bla KPC-2 with bla CTX-Mtype genes in K. pneumoniae was previously reported in Brazil [34] , China [35] , and Israel [31] but not in Greece.
To achieve the containment of the outbreak, infection control measures were intensified throughout the hospital (beginning November 2008). Dedicated infection control personnel were responsible for ensuring compliance with hand hygiene and contact isolation measures and adherence of personnel to meticulous environmental cleaning. Information on the number of new isolates was given daily by the laboratory, and cohorting of colonized or infected patients was practiced when possible. Restriction of the use of carbapenems was also enforced. The efficacy of this multidisciplinary effort cannot be assessed, because the outbreak was still ongoing at the end of the study period.
The susceptibility profile of the isolates recovered during the present outbreak (Tables 1 and 3 ) underscores the extremely limited therapeutic choices available for the treatment of infected patients. Colistin-containing combinations were most often used (Table 3) in our cohort. Surprisingly, fosfomycin was active in vitro against 54% of the isolates; however currently, in vivo efficacy of this bacteriostatic agent against KPC-2-producing K. pneumoniae has not been evaluated.
We described the emergence of KPC-2-producing K. pneumoniae in an institution where MBL-producing K. pneumoniae was endemic. Nevertheless, the outbreak strain rapidly disseminated from patient to patient, colonizing the gastrointestinal tract in some of them and causing severe infections shortly thereafter, contributing to death mainly among immunocompromised patients. These observations provide some insight into the epidemiology and the clinical importance of this new threat: namely, KPC-2-producing K. pneumoniae.
